Anna Wilkinson

Subscribe to all posts by Anna Wilkinson

Bill C-47 introduces patent term adjustment: Proposed term to run concurrently with term of Certificate of Supplementary Protection

By Kristin Wall, Anna Wilkinson and Paul Jorgensen on May 1, 2023 Posted in Intellectual property, Pharmaceuticals and life sciences

On April 20, 2023, the federal government tabled legislation (Bill C-47) that would amend the Patent Act to bring, for the first time, a system of general patent term adjustment (PTA) into Canada. Canada is required under the Canada-United States-Mexico Agreement (CUSMA) to adopt a PTA system by 2025. The PTA system is intended to … Continue reading

Consultation on proposed amendments to Patent Rules

By Anna Wilkinson, Christian Cawthorn and Tom Sutherland on July 18, 2021 Posted in Intellectual property

The Government of Canada has proposed a series of amendments to the Patent Rules intended to keep Canada compliant with its obligations under the Canada-United States-Mexico Agreement (CUSMA) and the Patent Cooperation Treaty (PCT). As part of the proposal, the Canada Gazette published a Regulatory Impact Analysis Statement on July 3, 2021, summarizing the changes and their anticipated impact. Interested persons have … Continue reading

New Federal initiatives to combat pandemic: Patent Act amended to allow limited government use of patented inventions for public health emergencies

By Chelsea Nimmo, Anna Wilkinson and Kristin Wall on March 25, 2020 Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences

On March 25, 2020, the Canadian Government passed into law Bill C-13, An Act respecting certain measures in response to COVID-19, following emergency sittings of Parliament and the Senate. Bill C-13 amends both the Patent Act and the Food and Drugs Act and may have implications for the pharmaceutical industry. Patent Act – Limited government … Continue reading